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Summary 
The studies reported here describe the isolation of peptides from MHC  class II molecules of 
murine macrophages infected with Leishmania donovani,  and the use of the derived peptide se- 
quences to rescue the pathogen peptide donor protein. The isolation of the peptides was  car- 
ried out by comparing the R.P HPLC profile of peptides extracted from infected macrophages 
with the peptides extracted from noninfected cells. Several distinct HPLC peaks unique to in- 
fected macrophages were sequenced.  One  of the peptides  that was  not homologous to any 
known protein was used to instruct the designing of an oligonucleotide sense primer that was 
used in combination with an oligo dT nucleotide (anti-sense primer) to amplify by PCR  a 
DNA fragment from L. donovani  cDNA. The amplified DNA fragment was cloned and used as 
a probe to screen a L. donovani  cDNA library. The cloned gene (Ld peptide gene) has an open 
reading  frame  of 525  bp  and  has  no  homology with  any  known  protein/gene  sequence. 
Northern blot analyses indicated that the Ld peptide/gene is broadly distributed and expressed 
among  species  of the  Leishmania  genus,  in  both  the  amastigote  and promastigote life cycle 
forms. Using the pGEX 2T vector, the gene was expressed and the relationship of the purified 
recombinant protein with L. donovani  was confirmed using both antibody and T  cell responses 
from immunized or infected animals.  The gene encodes a 23-kD molecule (Ldp 23) associated 
with the cell surface of L.  donovani promastigotes. In addition, T  cells purified from the lymph 
nodes of  BALB/c mice immunized with L. donovani  or infected with L. major, and from CBA/ 
J mice infected with L.  amazonensis were stimulated to proliferate by the recombinant Ldp 23 
and produced high levels oflFN-y and no IL 4. This observation suggests that the Ldp 23 is an 
interesting parasite molecule for the studies concerning the host/parasite interaction because 
the Thl pattern of cytokine response that it induces is correlated with resistance to Leishmania 
infections. These results clearly point to an alternative strategy for the purification of proteins 
useful  for the  development of both  vaccines and  immunological  diagnostic  tools  not  only 
against  leishmaniasis  but also for other diseases caused by intracellular pathogens. 
T 
he development of an immune response against  intra- 
cellular pathogens is strictly dependent on the ability 
of the  host  cell to process and present selected pathogen 
peptides in conjunction with MHC class I or class II mole- 
cules. MHC class I molecules present peptides processed in 
the cytosol whereas MHC  class II molecules present pep- 
tides processed in the endocytic vesicles  (l-3).  In general, 
the infection of a given cell by a virus results in processing 
and presentation of the pathogen peptide in the context of 
MHC  class I molecules. In contrast, peptides of pathogens 
that have tropism for the endocytic vesicles,  such as certain 
bacteria (e.g., Mycobacterium),  fungi (e.g., Paracoccidioides bra- 
ziliensis),  and protozoa (e.g.,  Leishmania)  are presented in 
the context of MHC class II molecules. The MHC class I 
molecules are expressed in virtually all cells. MHC class II 
molecules have a more restricted distribution and are ex- 
pressed mainly by cells of the immune system including B 
cells,  macrophages,  and  dendritic  cells.  Peptide  antigens 
that are bound by MHC  class I molecules are recognized 
by  cytolytic CD8  T  cells  whereas  peptides  that  interact 
with MHC  class II  molecules are recognized by CD4  T 
cells  (4,  5).  This molecular/cellular organization, in gen- 
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bution of physiological labor. Thus, class I molecules/CD8 
T  cells are involved with recognition and control of the re- 
activity  to  self molecules,  to  several  viral  antigens,  and 
other cytosolically processed antigens.  Class II molecules/ 
CD4 T  cells are usually associated with the recognition and 
control of foreign antigens  (intracellular pathogens includ- 
ing viruses) that are targeted to the intracellular vesicles (4, 
6). Both, class I and class II molecules have been character- 
ized by x-ray crystallography (7-9). It is generally accepted 
that the peptides present in the groove of the MHC  mole- 
cules are ultimately the structures responsible for the devel- 
opment not only of immunity to foreign antigens but also 
for the establishment of self tolerance by positive and nega- 
tive selection in the thymus (6, 10). Several groups have re- 
cently isolated naturally processed peptides bound to MHC 
class I and class II molecules and characterized them by di- 
rect  sequencing  or  by analogy to  synthetic peptides  (11- 
20). The class I binding peptides are usually 8-9 amino ac- 
ids. MHC  class II molecules, by contrast, derive their pep- 
tides from proteins that are degraded in cellular vesicles and 
are  usually  13-17  amino  acids  long  (21).  These  findings 
have  important  implications for  the  design  and  develop- 
ment of vaccines against a variety of intracellular pathogens 
because  they  provide  precise  information  about  the  epi- 
topes selected by the infected host cell. However,  thus far 
in  practically all  reported  studies,  the  peptides  that  have 
been isolated from MHC  class II molecules were obtained 
from  experimentally  noninfected  B  cells.  Most  of these 
peptides are derived from self proteins or are from proteins 
present  in  the  culture  medium.  The  present  study  was 
therefore  conducted  to  investigate  the  usefulness  of this 
novel approach to isolate peptides from experimentally in- 
fected cells. The protozoa Leishmania  donovani  was  chosen 
because this pathogen infects macrophages exclusively and 
resides inside the phagosome vesicles that comprise the cel- 
lular compartment where  most of the association between 
foreign peptides and MHC  class II molecules takes place. 
We demonstrate here that pathogen peptides can indeed be 
isolated from MHC  class II molecules of parasite-infected 
macrophages and also that this approach can be used to res- 
cue immunogenic  and potentially useful proteins from iu- 
tracellular pathogens. 
Materials  and Methods 
Animals,  Immunizations,  and mAb.  BALB/c mice (H-2  d) of both 
sexes were obtained from The Jackson Laboratory (Bar Harbor, 
ME) and were used at 8-14 wk of age. New Zealand white rab- 
bits were from Milbrook Farm (Amherst, MA). 
To  generate anti-L,  donovani--specific  T  cells,  BALB/c  mice 
were immunized in the rear foot pad with 5-10 ￿  10  6 promasti- 
gotes  emulsified in  complete  Freiind's adjuvant  (CFA)  1 (Difco 
Laboratories,  Madison,  MI)  as  described  (22).  The  draining 
1Abbreviations used in this paper: CFA, complete Freiind's adjuvant; GST, 
glutathione S-transferase; IFA, incomplete Freiind's adjuvant; IM, intra- 
muscular; IPTG, isopropyl-13-thiogalactopyranoside;  NGS, normal goat 
serunl. 
lymph nodes were excised 8 d after the immunization and the T 
cells were purified as described below. For the anti-recombinant 
protein antibody production, BALB/c mice were immunized in 
the rear foot pad with 5-10  pug of protein emulsified in  CFA. 
The mice were boosted 7 d later with 5-10 pug of protein emulsi- 
fied in incomplete Fre~nd's adjuvant  (IFA) inoculated into  the 
peritoneal cavity. The mice were bled 7 d after the second immu- 
nization. The protocol for the rabbit immunization was: one in- 
tramuscular (IM) injection of 25-30 pug of purified recombinant 
protein emulsified in CFA into each thigh on day one; one IM 
injection of 25-30 pug of purified protein emulsified in IFA into 
each shoulder on day 7; on day 15, 25-30 pug of the purified pro- 
tein in PBS was injected into the subcutaneous tissue.  The rabbit 
was bled 7 d after the last immunization. 
Culture  supernatants  of MK-D6  hybridoma cells  (American 
Type Culture Collection, Rockville, MD) were employed as the 
source for anti-MHC class II (H-2  d) monoclonal antibody. Pro- 
tein  concentration was  determined using the  Bio-Rad Protein 
Assay reagent (Bio-Rad Laboratories, Richmond, CA). 
Tissue Culture and Cell Lines.  The  medium  used  for  tissue 
culture  was  BruiTs supplemented  with  L-glutamine,  10%  FCS 
(HyClone Laboratories Inc., Logan, UT),  and gentamicin. The 
macrophage  cell line P338D1  (H-2  a)  was  a  gift of Dr.  Martin 
Doff (Harvard Medical School, Boston, MA). All cultures were 
performed at 37~  in 5% CO2. Lymph node T cells were purified 
in an anti-mouse Ig column to remove the B cells (23) followed 
by  a  passage  through  a  Sephadex  G10  column  to  remove  the 
macrophages  (24).  Mitomycin  treated  BALB/c  mouse  spleen 
mononuclear cells were used as antigen presenting cells  (APC). 
To assay for in vitro antigen-specific T  cell response, 2 X  10 s an- 
tigen pulsed APC were cultured for 3 d with 10  s purified T  cells 
and  proliferation  was  measured  by  [3H]thymidine  (DuPont- 
NEN, Boston, MA) incorporation. 
Leishmania' Maintenance and Macrophage Infection.  L.  donovani (1S 
strain),  L.  amazonensis  (MHOM/BR/77/LTB0016),  L.  major 
(MHOM/IR/79/LRC-L251),  and L. pifanoi  (MHOM/VE/60/ 
Ltrod)  promastigotes were  grown  and  maintained  at  26~  in 
Schneider's medium containing 20%  FCS and 50  p,g/ml genta- 
micin. The amastigote forms of L.  amazonensis  were obtained by 
differential centrifugation of a  "pus-like" foot  pad  lesion  of a 
CBA/J  mouse  infected for  6  mo  with  this  parasite. L.  pifanoi 
amastigotes were obtained from axemic culture as previously re- 
ported (25).  Infection of the macrophage cell line P388D1  with 
L. donovani promastigotes was carried out for an initial incubation 
of 6 h at room temperature. The cultures were then transferred to 
37~  for additional incubation periods. At a ratio of 3-5 parasites 
per macrophage nearly 90% of the macrophages were infected af- 
ter 24 h of incubation at 37~ 
Purification of MHC  Class H-associated  Peptides from  P388D1 
Macrophages Infected with L.  donovani.  Approximately 1.5  X  101~ 
L.  donovani-infected  or an equal number of noninfected P388D1 
macrophages were used for each purification. The cells were har- 
vested, washed with PBS and incubated for 30 min in cold lysis 
buffer (PBS,  1% Nonidet P40, 25 mM iodoacetamide, 0.04%  so- 
dium azide, 1 mM aprotonin, and 1 mM PMSF). The insoluble 
material was removed by centrifugation at 40,000 g for 1 h  and 
the supernatant was recycled overnight at 4~  over a 5 ml anti- 
MHC  class II  molecules  (H-2  a)  Sepharose  column  (Protein  G 
Sepharose column  to  which the  monoclonal antibody MK-D6 
had been bound).  The  column was washed with 50  rnl of lysis 
buffer and then with 50 ml of PBS  containing 0.5%  octyl glu- 
copyranoside detergent. Bound molecules were eluted from the 
column with  IM acetic acid in 0.2%  NaCI. The MHC/peptide 
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Centricon 100 filter unit (Amicon Division, W.R. Grace & Co., 
Beverly, MA). The peptides were then dissociated from the class 
II molecules by the addition of acetic acid to 2.5 M, followed by 
separation using a Centricon 10 filter unit. The resulting peptide 
preparation, present in  the  low  molecular weight  sample,  was 
then  dried using  a  speed vac  concentrator  (Savant  Instrument 
Inc., Farmingdale, NY). The peptides were redissolved in 200 Ixl 
of 0.05% TFA and separated by reverse-phase high performance 
liquid chromatography (RP-HPLC)  using a  2.1  mm  ￿  25  cm 
Vydac C-18 column at a flow rate of 0.15 ml/min employing a 
1-30% acetonitrfle gradient (60 rain) followed by 30-60% gradi- 
ent (30 rain) and the 60-80% gradient (90-110 rain). 
Sequences of I-A  d and I-E&assodated Peptides.  The RP-HPLC sep- 
arations were analyzed by comparing the UV-absorption profiles 
from preparations of MHC  class II-associated peptides from in- 
fected and noninfected macrophages. Selected peaks, unique  to 
the infected macrophages, were sequenced by Edman  degrada- 
tion on a gas-phase protein sequencer (model 477;  Applied Bio- 
systems,  Inc., Foster City, CA). Protein sequence and amino acid 
analysis were performed by the W. M.  Keck Foundation, Bio- 
technology Resource Laboratory (Yale University, New Haven, 
CT). Amino acid sequences were searched for identity with pro- 
teins in the  GenBank database using the GENPETP,  PIR,  and 
SWISSPROT programs. 
PCR.  A peptide-derived oligonucleotide (5'-GGAATTCC- 
CCInCAGCTInGTInTTCGAC-3')  containing  an  EcoRI  re- 
striction endonuclease site (underlined) and a poly-thymidine oli- 
gonucleotide (oligo dT, downstream primer) containing a XhoI 
restriction endonuclease site,  were  used  to  amplify by PCR  a 
gene fragment from a L.  donovani  promastigote cDNA prepara- 
tion. The reaction conditions were: one cycle of 3 min at 94~ 
immediately followed by 35  cycles of I  rain at 94~  1 rain at 
45~  and 1 inin at 72~  The L.  donovani  cDNA was prepared 
from  5  ￿  10  v washed promastigote forms  harvested at the log 
growth phase  (3-d culture).  The  cDNA was obtained using an 
Invitrogen cDNA cycle  TM  kit (Invitrogen Co., San Diego, CA). 
Oligonucleotide primers were synthesized by the DNA Synthesis 
Laboratory, Department of Pathology (Yale University School of 
Medicine). 
Gene Cloning  and DNA  Sequencing.  The PCR amplified gene 
fragment was ligated into the pCR  TM  vector using the TA clon- 
ing system (Invitrogen). Transformants were selected in LB me- 
dium containing 100 ~xg/ml ampicillin and the plasmid DNA was 
isolated  using  the  Wizard  TM  Minipreps  DNA  purification  kit 
(Promega Co., Madison, WI). Insert DNA was released with the 
restriction enzymes  EcoRI  and  XhoI  (New  England  Biolabs, 
Beverly, MA), purified from an agarose gel electrophoresis and 
labeled with 32p using random priming method (Megaprime La- 
beling Kit; Amersham Life Science, Buckinghamshire, England). 
This DNA fragment was used as a probe to screen a L.  donovani 
promastigote cDNA library (26). The gene encoding the protein 
containing  the  MHC  class  II-associated peptide  (Ld  peptide/ 
gene) was excised from the phagemid by in vivo excision using 
the Stratagene protocol. DNA sequencing was performed using 
the  Sequenase  version 2  system  (DNA  sequencing  kit)  in  the 
presence or absence of 7-deaza-GTP (United States Biochemical, 
Cleveland,  OH).  Sequence  analysis  was  performed  using  the 
University of Wisconsin  Genetics  Computer  Group  Programs 
and the GenBank and EMBL data bases of protein and DNA se- 
quences. 
Bacterial Expression and Purification of Recombinant Protein.  PCR 
was  used to subclone the cloned gene in frame into the expres- 
sion vector pGEX 2T. Primers containing the appropriate restric- 
tion  site enzymes, initiation and termination codons were: 5'- 
GGATCCATGGTCAAGTCCCACTACATCTGC-3'  for  the 
upstream  primer  and  5'-GAATTCAGACCGGATAGAAAT- 
AAGCCAATGAAA-3' for the  downstream primer (restriction 
sites  of BamHI  and EcoRI  are underlined, respectively). PCR 
conditions were as the indicated above for the amplification of 
the  original peptide related DNA fragment.  The  template used 
was  pBluescript plasmid containing the  cloned  gene  from  the 
cDNA library. Overexpression of the recombinant fusion protein 
was  accomplished  by  growing  the  transformed  Escherichia  coli 
(DH5oL) and inducing the tac promoter with 1 mM isopropyl-13- 
thiogalactopyranoside (IPTG)  (Stratagene,  La Jolla,  CA).  Cells 
were collected, centrifuged, and analyzed for the presence of the 
fusion protein by SDS-PAGE. Purification of the fusion protein 
could not be done by aflqnity chromatography because of its high 
insolubility. To circumvent this problem the protein was purified 
from a preparative SDS-PAGE electrophoresis. The band was vi- 
sualized with 0.1 M  KC1, cut and electroeluted from the gel fol- 
lowed by  extensive dialysis against PBS  and  concentration  on 
Centricon 10 filters. 
Northern  Blot Analysis.  The RNA was prepared from 2 ￿  107 
parasite cells using the Micro RNA isolation kit (Stratagene) ac- 
cordingly to the company's recommended instruction. RNA was 
prepared  from  L.  donovani  promastigotes  (logarithmic  growth 
phase);  from L.  major promastigotes (logarithmic and stationary 
growth phases);  from L.  amazonensis,  both promastigotes (loga- 
rithmic and  stationary growth  phases)  and  amastigotes purified 
from CBA/J-infected mice; and from L. pifanoi,  both promastig- 
otes (logarithmic and stationary growth phases)  and amastigotes 
(from axenic culture medium). The hybridization was carried out 
at 45~  in the presence of 50% formamide, 5￿  Denhardt's solu- 
tion, 0.1% SDS, 100 I~g/ml single stranded salmon sperm DNA, 
and 5￿  SSPE  using 0.45-~m  Nytran membrane filters  (Schlei- 
cher & Schuell, Keene, NH). The probe was the 32p-labeled Ld 
peptide/gene as indicated above. 
Western Blot Analysis.  Approximately 2  ￿  10  6  L.  donovani 
promastigotes (log phase)  were  lysed with  SDS-PAGE loading 
buffer and separated under reducing conditions using a 15% poly- 
acrylamide gel. The proteins were transferred onto 0.45-1xM  Im- 
mobilon-P transfer membrane (MiUipore Co., Bedford, MA) us- 
ing a  wet-type electroblotter (Mini  Trans-Blot Electrophoretic 
Transfer Cell; BioRad Life Science Division, Richmond, CA) for 
2  h  at 50 V.  The membranes were blocked overnight at room 
temperature with PBS containing 3% normal goat serum (NGS), 
0.2%  Tween-20,  and  0.05%  sodium  azide,  followed by  three 
washes with PBS. The blots were then incubated for 3-4 h at 4~ 
with  several dilutions  of anti-recombinant protein  antisera  (or 
control sera). The sera were previously absorbed 2￿  with nonvi- 
able desiccated Mycobacterium tuberculosis H-37 RA (Difco Labora- 
tories)  and  were  diluted in  PBS  containing  1%  NGS  and  5% 
powdered nonfat  bovine  milk  (Carnation,  Nestl~  Food Com- 
pany,  Glendale, CA).  The  membranes were  then  washed with 
PBS, incubated for 1 h at room temperature with goat anti-rabbit 
IgG (or goat anti-mouse IgG) antibody conjugated with alkaline 
phosphatase  (Promega),  washed  once  with  PBS  and  2X  with 
veronal buffer, pH 9.4. The reaction was visualized using the sub- 
strate  mixture  5-bromo-4-chloro-3-indolyl-phosphate and  ni- 
troblue tetrazolium (Kirkegaard & Perry Laboratories Inc., Gaith- 
ersburg, MD) according to the manufacturer's instructions. 
Flow  Cytometry.  L.  donovani  promastigotes (log phase)  (3  ￿ 
106/100  ILl) were washed 3X with staining buffer (PBS contain- 
ing 3% FCS and 0.1% sodium azide) and then incubated for 1 h at 
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tein antisera or control sera. The parasites were washed 3￿  with 
staining buffer and incubated for 45 rain at 4~  with FITC-con- 
jugated rabbit anti-mouse IgG/IgM antibody (HyClone Labora- 
tories  Inc.).  The  promastigotes were  washed  3￿  at  4~  with  .~ 
staining buffer and the intensity of fluorescence was analyzed (un-  .=. 
gated) by flow cytometry using a FACScan (Becton Dickinson,  0= 
Sunnyvale, CA). 
n  Cytokine Analysis￿9  The levels of IFN-'y and IL 4 were mea- 
sured by ELISA as previously described (27-29) using specific anti 
IFN-',/and IL 4 mAbs (PharMingen, San Diego, CA). 
Results 
Peptides Extracted from MHC  Class II Molecules of L.  dono- 
vani-infected P3  88D1 Macrophages Display a Distinct HPLC Pro- 
file.  To  ascertain  that  in  vitro  infection  of macrophages 
would  load  their  MHC  class  II  molecules  with  parasite 
peptides,  initial  experiments  were  carried  out  to  test  the 
abihty  of the  L.  donovani-infected  macrophage  cell  line 
P388D1  to present parasite antigens to L.  donovani-specific 
T  cells. This macrophage cell line was chosen because it has 
the same H-2 haplotype as the BALB/c mouse, which is a 
strain of mouse moderately susceptible to L. donovani infec- 
tion and selected to conduct the in vivo experiments. Us- 
ing a proportion of 3-5 parasites per cell and an initial in- 
cubation at room temperature for 4-6 h  followed'by 37~ 
for  24-48  h,  close  to  90%  of the  macrophages  were  in- 
fected. The level of MHC  class II molecules expression as 
determined by FACS analysis, indicated that infection did 
not cause an effect on the levels of MHC  class II expression 
when  compared to noninfected control cells (not shown). 
To test the ability of the L.  donovani-infected P388D1  cells 
to present parasite antigens, macrophages were  infected as 
indicated above and incubated at 37~  for either 24, 48, or 
72  h.  At each  of these  time points  the  nonadherent  cells 
and free parasites were washed  out and  the  adherent  cells 
were mechanically dislodged, washed, and fixed with para- 
formaldehyde. These cells were then used as APCs for pu- 
rified lymph node T  ceils from BALB/c mice immunized 
with  L.  donovani  promastigotes  emulsified  in  complete 
Frefind's adjuvant. Results in Fig.  1 indicate that L.  dono- 
vani-infected  P388D1  macrophages  process  parasite  anti- 
gens and that optimal presentation occurs after 48 h  of in- 
fection.  No stimulation of the T  cells by the  noninfected 
macrophages  was  observed.  To  isohte the MHC  class II- 
associated L. donovani peptides, P388D1  macrophages were 
infected for 48 h  and the MHC  class II molecules were af- 
finity purified as indicated in Material and Methods.  Pep- 
tides were then obtained by acid elution and filtration over 
a  Centricon  10 membrane and fractionated by RP-HPLC 
on  a  C18  column.  Noninfected  P388D1  ceils were  simi- 
larly processed to serve as a background control for endog- 
enous  MHC  class  II-associated peptides.  Fig.  2  shows  a 
representative  experiment;  four  distinct  peaks  that  are 
present  only  in  the  material  isolated from  infected  mac- 
rophages are indicated. 
Amino Acid Sequence of Peptides Isolated from MHC Class II 
of Infected P388D1 Macrophages.  Out of three independent 
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Figure  1.  Presentation of para- 
site epitopes to specific T cells by 
P338D1  macrophages infected 
with L. donovani. P388D1 macro- 
phages were infected with L. dono- 
vani promastigotes for an initial pe- 
riod  of 6  h  at  26~  and  then 
incubated at 37~  for 24, 48, and 
72 h. At each of these time points 
the nonadherent macrophages and 
free  parasites were  removed  and 
the adherent cells were mechani- 
cally dislodged, washed, and fixed 
with paraformaldehyde.  These cells 
were  then  washed and  used  as 
APCs (2 ￿  10S/well)  for a purified 
T  cell preparation (10  s cells/well) 
obtained  from  lymph  nodes of 
BALB/c  mice  immunized  with 
L. donovani promastigotes. Stimulation index was calculated by dividing 
the  CPM  obtained for  the  cells cultured  in  the  presence of infected 
P388D1 macrophages by the CPM obtained for the cells cultured in the 
presence of noninfected macrophages but submitted to the same condi- 
tions of the infected macrophages. 
peptide extraction,  25  distinct HPLC  peptide peaks were 
isolated from  L.  donovani-infected  macrophages  and  were 
subjected to protein sequence analysis using automated Ed- 
man  degradation.  In  practically al/  determinations  no  as- 
signment could be made for the first position. Also, in most 
cases the  definition of the  amino  acid residue of the  next 
10-15 positions was usually based on the quantitative dom- 
inance of one residue over others. Using this approach, the 
sequences  obtained for several peptides showed  the pres- 
ence  of 3--6  different residues in  many  of the  10-15  se- 
quence cycles analyzed for each determination. Similar ob- 
servations were recently reported for peptides isolated from 
MHC  class  I  molecules  of Listeria  monocytogenes-infected 
macrophages (30) and reflects a mixture of peptides. In ad- 
dition,  sequences  could  not  be  obtained  for  some  peaks 
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Figure 2.  HPLC profile of peptides isolated from purified MHC class 
II molecules from P388D 1 macrophages.  Peptides were isolated  from non- 
infected (A) or from L. donovani infected (B) P388D1 macrophages and 
submitted to P..P-HPLC in a Vydac C-18 column. The arrows in B indi- 
cate peptide peaks present ordy in the infected macrophage preparation. 
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were  blocked.  Notwithstanding,  three  peptide  sequences 
were determined (Table 1). The sequence data base analysis 
revealed that one of the peptides was highly homologous to 
glyceraldehyde-3-phosphate dehydrogenase of various spe- 
cies. Another peptide had homology with elongation factor 
of several species, including leishmania. The third sequence 
was not clearly related to any known proteins. 
Cloning and Sequencing the L. donovani Gene (Ld Peptide/ 
Gene) That Encodes the Peptide Donor Protein.  In order to re- 
trieve  the  L.  donovani protein  that  was  processed  into  a 
peptide associated with the MHC class II molecules of in- 
fected macrophages, the peptide sequence of uncertain ori- 
gin was chosen (Table 1) to guide the strategy to clone the 
corresponding parasite gene. A DNA fragment was initially 
amplified from L.  donovani promastigotes cDNA by PCR. 
The sense primer was a peptide based oligonucleotide  (see 
Materials and Methods). The bases were selected following 
the  preferential  codon  usage  of L.  donovani (31).  Inosine 
was used for the residues of positions 4, 6, and 7 because of 
the low codon usage assurance for the corresponding amino 
acids.  In  addition,  the  carboxyl-terminal L-glutamic  acid 
was not  included  for the  design  of the  primer.  The  anti- 
sense primer was oligo dT. PCR was carried out for 35 cy- 
cles and the products were analyzed by gel electrophoresis. 
Only  one  band  of ,'-~300 bp  was  obtained  (Fig.  3).  This 
fragment was  cloned  and  its  sequence  confirmed  the  se- 
quence of the peptide-based primer including the glutamic 
acid  codon,  deliberately  not  included  in  the  primer  se- 
quence. The 300-bp insert was isolated and used as a probe 
to screen an L. donovani cDNA library. An ,~650-bp cDNA 
gene (Ld peptide/gene) was cloned and sequenced (Fig.  4). 
The sequence data indicated complete homology with the 
original 300-bp PCR fragment. A 525-bp open reading frame 
containing an ATG codon that follows the last four bases of 
the spliced leader sequence and three stop codons adjacent 
to the poly A  tail was identified.  This frame also codes the 
carboxyl-terminal sequence (KVFDE) of the purified MHC 
class II associated peptide. The sequence analysis  of the de- 
duced  protein  sequence  revealed  one  potential  glycosyla- 
tion site (Asn-Cys-Ser) at positions 68-70.  The search for 
homology of the  Ld peptide/gene with  known sequences 
Figure  3.  PCR amplification of a 
L. donovani cDNA fragment  encoding 
the  peptide isolated from the  MHC 
class II molecules. L. donovani promas- 
tigote cDNA was used as template and 
the sense primer was a peptide-based 
deoxyribo  oligonucleotide and  the 
anti-sense primer was  a poly-thymi- 
dine  oligonucleotide. Amplification 
was performed  as described in Materi- 
als and Methods and the PCR product 
was  analyzed by  agarose (1.5%) gel 
electrophoresis. Lane A,  control (no 
template added to the reaction); lane 
B, PCR amplified product. Numbers 
on the left side indicate the molecular 
weights of  the markers  in base pairs. 
was carried out using the FASTA program for both nucle- 
otide and peptide revealed no significant homology. 
Expression of the Ld Peptide  / Gene in Leishmania Organisms. 
To ascertain that  the  Ld peptide/gene  is  expressed in  the 
Leishmania  organisms,  a  Northern  blot  analysis  was  per- 
formed using RNA  prepared from different promastigote 
growth  phases  (logarithmic  and  stationary)  and  from  the 
amastigote form of these parasites. The reason to investigate 
the mRNA expression in all the leishmania growth phases 
and forms is based on the infection pattern of these para- 
sites:  the amastigote is the form adopted by these parasites 
in  the  vertebrate  host;  and  for some  leishmanias  (e.g., 
L.  major) the  stationary growth phase of the promastigote 
form is correlated with high infectivity (32).  RNA was pre- 
pared from: logarithmic growth phase of L.  donovani pro- 
mastigotes; from logarithmic and stationary growth phases 
of L.  major promastigotes;  and  from promastigotes  (loga- 
rithmic and stationary growth  phases)  and amastigotes of 
L.  amazonensis and L. pifanoi. Fig.  5  shows that one single 
RNA band of 680  bp was observed for all growth phases 
and forms of all tested Leishmania. This result is consistent 
with  the  corresponding gene  size  (525  bp)  and  with  the 
MW  of the  expressed  protein  (see  section  below)  and 
points to the ubiquitous  distribution and expression of this 
gene within the genus Leishmania. 
Table 1.  Amino  Acid Sequence Analysis of Purified MHC Class II-associated Peptides  from L. donovani-infected P388D1 Macrophages 
Sequencing cycle 
Peptide  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  Homology 
1  X  G  V  N  G  F  G  R  I  G  R  L  V  T  R  A 
2  X  N  I  V  V  I  G  H  V  D  S  G  K  S  T  X 
3  X  Q  X  P  Q  L  V  F  D  E  X  X 
(K) 
Glyceraldehyde-3-phosphate  dehydrogenase 
Elongation  factor 
Unknown 
X indicates that no amino acid could be assigned for that position. Remaining letters stand for the amino acid code. In parenthesis is an alternative 
amino acid for position 6 ofpeptide 3. 
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M  V  K  S  H  Y  I  C  A  G  R  L 
1  AATTC  GGCACGAGGCATTGTGCATAATGGTC  AAGTC  CCAC  TACATC  TGC  GCGGC-C  C  GC  C  T 
20  30 
V  R  I"  L  R  G  P  R  Q  D  R  V  G  V  I  V  D  I  V  D 
61  GGTGC  GCATC  C  TGCGTGGC C  CC  CGC  CAGGAC  CGCGTTGGTGTGATCGTCGAC  ATTGTCGA 
40  50 
A  N  R  V  L  V  E  N  P  E  D  A  K  M  W  R  H  V  Q  N 
121  C  GCGAACCGCGTC-C TGGTGGAGAAC C  CGGAGGACC-CGAAGATGTGGCGC  CAC  GTGCAGAA 
60  70 
L  K  N  V  E  P  L  K  Y  C  V  S  V  S  R  N  C  S  A  K 
181  C  C  TGAAGAACGTC4~AGCCGCTGAAGTAC  TGCGTGAGCGTCAC-CCGCAACTC-CAGC  GCGAA 
80  90 
A  L  K  D  A  L  A  S  S  K  A  L  E  K  Y  A  K  T  R  T 
241  GGCC-CTGAAGGATGCGC TGGC  C  TCGTCGAAC-GCC-CTGGAGAAGTACGCC*AAGACGCGC  AC 
100  110 
A  A  R  V  E  A  K  K  A  C  A  A  S  T  D  F  E  R  Y  Q 
301  TGCTGC GC  GCGTGGAGGCGAAGAAGGCGTGCGC  C  GCGTCGACGGACTTC  GAGCGC  TACCA 
120  130 
L  R  V  A  R  R  S  R  A  H  W  A  RI  K  V  F  D  EIK  D 
1  1 
361  GC  TGC  GC  GTTGC  GC  GCCGTTC TC  GCGC  GCAC  T~C-CC-CAAGGTGTTCGACGAGAAGGA 
140  150 
A  K  T  P  V  S  W  H  K  V  A  L  K  K  M  Q  K  K  A  A 
421  C  GC  GAAGACGC C  CGTGTCGTGC~AC~GGTTGC  GC  TGAAGAAGATGCAGAAGAAGGC  C  GC 
160  170 
K  M  D  S  T  E  G  A  K  R  R  M  Q  K  A  I  A  A  R  K 
481  AAAGATGGAC  TCGACCGAGGGCGCTAAGAGGC  GCATGCAGAAGGCGATC  GCTGC  CC  GCAA 
A  K  K  *  * 
541  GGCGAAAAAGTAAGGC  CATAC  C  C  TCAC  TTCGC  TTGTTT  CGTGATTTTTC  GTGGGAGTCGG 
601  TGGC  C  CTACCACCGGTCTTTCATTGGCTTATTTCTATC  CGGTC  TGAAAGAGGTAC  AAAAA 
661  AA~ 
Figure 4.  Nucleotide  sequence and deduced  amino acid sequence of 
the Ld peptide/gene  cDNA. Numbers on the right refer to the nucleotide 
positions and the numbers above the protein sequence refer to the amino 
acid positions. The sequence of the last presumptive four bases of the 3' 
end of the spliced leader DNA sequence is underlined.  Putative transla- 
tion initiation is indicated as amino acid position  1 (Met), which corre- 
sponds to the first ATG codon after the spliced leader sequence. Potential 
glycosylation site (Asn-Cys-Ser) is double underlined. Three stop codons 
preceding the poly A tail are marked by asterisks. The protein sequence 
that matches the five carboxy-terminal amino acids (KVLDE) of the pep- 
tide isolated from  the MHC  class-II molecules of L.  donovani-infected 
macrophages is indicated in the boxed residues. These data are available 
under GenBank/EMBL accession number X86551LDP23CSPlk. 
Identification  and  Purification of the L.  donovani  Peptide Do- 
nor Protein.  The  recombinant L.  donovani  peptide  donor 
protein  was  produced  in  E.  coli  transformed  with  the 
pGEX 2T expression vector in which the Ld peptide/gene 
was subcloned in frame. A  glutathione-S-transferase fusion 
protein of 43-44 kD was produced (Fig. 6 A) therefore in- 
dicating a  leishmanial protein  of approximately  18  kD,  as 
glutathione S-transferase  (GST)  has a  molecular weight  of 
26 kD.  However the fusion protein was very insoluble and 
therefore  could not be purified by affinity chromatography 
using a glutathione column. The use of low concentrations 
of detergents  like  SDS,  sarcosyl,  deoxycholate,  and octyl- 
glucopyranoside during the extraction steps was efficient to 
solubilize the fusion protein but unfortunately prevented its 
binding to the glutathione column (not shown). Other ma- 
neuvers,  such  as  the  growth  of the  E.  coli  and incubation 
and induction of the  tac promoter with IPTG at 33~  did 
not improve the protein solubility (not shown).  However, 
the  purification was  achieved  by preparative  SDS-PAGE. 
Approximately  500  ~g  of purified  protein  was  obtained 
(Fig.  6  B).  Attempts to  further purify the leishmanial pro- 
tein by cleaving it out from  the  fusion protein  GST with 
thrombin were unsuccessful (not shown). 
Purified Recombinant Protein Induces  Anti-L.  donovani Antibody 
Response in Mice and Rabbits.  In  order  to  evaluate  the  ira- 
Figure 5.  Expression of the Ld 
peptide/gene.  Total  RNA  was 
prepared  from  L.  donovani pro- 
mastigotes, L.  major, L.  amazon- 
ensis, and L. pifanoi and used for 
Northern blot analysis. Blot was 
hybridized  with  32p-labeled Ld 
peptide/gene  cleaved  from 
pBluescript plasmid. 1, 2, and 3 
refer  to  RNA  obtained  from 
promastigotes at the logarithmic 
growth  phase, promastigotes  at 
the stationary growth  phase and 
from  amastigote  forms, respec- 
tively. Numbers on the left side 
indicate the molecular weights of 
the markers in base pairs. 
munogenicity of the  recombinant leishmanial protein and 
to  investigate its expression in the parasites,  mice and rab- 
bits were immunized with the GST-fusion protein in CFA. 
Sera  were  prepared  and  the  anti-leishmania Ab  response 
was measured by Western blot analysis and by FACScan. In 
both cases  L.  donovani  promastigotes  were  used as antigen. 
Fig. 7  shows that the rabbit anti-recombinant protein anti- 
serum  detects  a  single protein  of 23  kD  (Ldp  23)  in  the 
leishmania  crude  extract  antigen  preparation.  No  bands 
were  observed when an anti-GST antiserum was used (not 
shown).  Moreover,  the  FACScan  analysis  (Fig.  8)  shows 
that the Ab induced by the recombinant Ldp 23 reacts with 
intact live L.  donovani promastigotes, thus pointing to a cell 
surface expression of this molecule on these organisms. 
Leishmania-specific  Lymph  Node  T  Cells Recognize  the Re- 
combinant Ldp  23.  To test the responsiveness of T  cells to 
Figure 6.  Expression of the Ld 
peptide/gene  as  a  recombinant 
GST fusion protein.  (A)  E.  coil 
(DH  500  transformed  with  the 
expression  vector  pGEX  2T 
containing the  Ld peptide/gene 
was  grown in LB  medium and 
the  tac  promoter  was  induced 
with  IPTG  for  3  h.  The  cells 
were  pelleted,  resuspended  in 
loading buffer and submitted  to 
SDS-PAGE  (10%) under reduc- 
ing conditions. The gel was stained with Coomassie blue. Lane I, E. coli 
transformed with pGEX 2T, noninduced;  lane 2, E. coli transformed with 
pGEX 2T, IPTG induced. Arrow indicates the recombinant fusion pro- 
tein. (B) Transformed E. coli  was induced and lysed as in A and submitted 
to  a preparative SDS-PAGE.  The band corresponding  to the over  ex- 
pressed recombinant fusion protein was identified by KC1, cut out, elec- 
troeluted from the gel strip, dialyzed against PBS, and then submitted to 
analytical SDS-PAGE (12%). Numbers on the left side indicate the mo- 
lecular weights of the markers. 
1428  Cloning a Leishmania Gene Using an MHC Class lI-associated Peptide the  Ldp  23  protein,  two  sets  of experiments were  per- 
formed. Initially, BALB/c mice were immunized with pro- 
mastigote forms of L.  donovani in CFA. T  cells were puri- 
fied from draining lymph nodes 8 d after the immunization 
and were stimulated to proliferate with mitomicin-treated 
mononuclear spleen cells  (APC)  pulsed with  the  purified 
recombinant fusion protein. Fig. 9  shows that leishmania- 
specific T  cells proliferate well and in a dose response man- 
ner  to  recombinant Ldp  23.  No  response  was  observed 
when purified GST was added instead of the recombinant 
fusion protein nor lymph node T  cells from mice immu- 
Figure  7.  Western  blot analysis of L.  donovani 
promastigote antigens.  Parasites (2 ￿  106) grown in 
Schneider's medium  for  3  d  (log phase) were 
washed with PBS, lysed with SDS-PAGE loading 
buffer, and submitted to electrophoresis under re- 
ducing conditions in a 15% gel. The proteins were 
transferred to Immobilon-P membranes and incu- 
bated with a 1/200 dilution of preimmune rabbit 
serum (lane  A) or with the same dilution of anti-fu- 
sion protein rabbit antiserum (lane B).  Reaction 
was detected using a phosphatase conjugated goat 
anti-mouse immunoglobulins. Arrow points to  a 
molecule detected by the specific antibody. Num- 
bers on the left side indicate the molecular  weights 
of the markers. 
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Figure  8.  Surface expression 
of Ldp  23  on L.  donovani pro- 
mastigotes. Indirect immunoflu- 
orescence was  performed with 
hve L. donovani  promastigotes  us- 
ing  preimmune  mouse serum 
(dotted line) or mouse anti-GST- 
Ldp  23  antiserum (solid line). 
Both sera were diluted at 1/100. 
Parasites were washed with stain- 
ing  buffer and  incubated with 
FITC  conjugated goat anti- 
mouse  immunoglobuhn  anti- 
body.  Fluorescence intensity 
was analyzed  by FACScan. 
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Figure 9.  Stimulation  ofleish- 
mania-specific  T cells to prolifer- 
ate by Ldp 23. T cells (105/well) 
were purified from lymph nodes 
of BALB/c mice immunized in 
the  foot pad  with  L.  donovani 
promastigotes in CFA and were 
cultured with various concentra- 
tions of the purified recombinant 
Ldp 23 in the presence of 2 ￿ 
10  s mitomycin C treated normal 
BALB/c  spleen mononuclear 
cells as APC. Prohferation of the 
T ceUs was measured at 72 h of 
culture. Values are  expressed as 
cpm and represent the mean of 
[3H]TdR incorporation of tripli- 
cate cultures. Background cpm 
of cells (T cells + APC) cultured 
in the presence of medium alone 
was 1291. 
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Figure 10.  Ldp 23-induced cytokine production by lymph node cells 
of L. major-infected BALB/c mice. Cells (2.5 ￿  106) obtained from the 
draining popliteal  lymph node of BALB/c mice infected in the foot pad 
with L. major  3 wk previously,  were cultured for 72 h in the presence of 
recombinant  Ldp 23 or leishmania  lysate. Culture supematants  were col- 
lected and assayed by ELISA for the production of IFN-~/ (A) and IL-4 
(B). No cytokine could be detected in supernatants  ofnonstimulated cells. 
nized with CFA alone were stimulated to proliferate in the 
presence  of the  leishmanial fusion  protein  (not  shown). 
The recognition of the recombinant Ldp 23 by leishmania- 
specific T  cells was also tested using two murine models of 
leishmaniasis, the L.  major highly susceptible BALB/c mice 
and the  L.  amazonensis susceptible CBA/J mice (33).  These 
models were selected to investigate the cytokine pattern in- 
duced by Ldp 23. In the mouse model ofleishmaniasis, re- 
sistance is associated with Th 1 cytokines whereas suscepti- 
bility is linked to  Th 2  responses (34).  Lymph node cells 
were  obtained  3  wk  after  the  initiation of infection of 
BALB/c mice with L.  major and the ability of these cells to 
recognize the recombinant Ldp 23 was measured by prolif- 
eration and by the production of the cytokines IFN-~/and 
IL-4.  Ldp  23  did  stimulate these  cells  to  proliferate  (not 
shown) and induced typical Th 1 type of cytokine response 
as indicated by the production of high levels of IFN-~/and 
no IL-4 (Fig. 10).  Stimulation of these cells with a leishma- 
nia crude lysate yielded a mixed Th cytokine profile. Ex- 
acdy the same pattern of cytokine production was obtained 
from  the  CBA/J  mice  infected with  L.  amazonensis  (not 
shown). These results clearly indicate that Ldp 23 is a pow- 
erful and selective activator of Th  1  cytokines by mouse 
cells. 
Discussion 
The isolation and characterization of peptides associated 
with  MHC  molecules has  been  a  focus  of intensive re- 
search over the past 4--5 yr. These studies clearly have de- 
fined new and solid concepts in the biology and molecular 
events of antigen processing, presentation, and recognition. 
However, much of this progress was made possible because 
of the  continuous advancement in methodologies  of in- 
creasing sensitivity, specificity and reproducibility for  the 
isolation and characterization of minute amounts of pep- 
tides  (35).  The  present  investigation utilized  these  new 
concepts and tools as an approach to  define novel protein molecules involved in the host-pathogen interaction. The 
studies reported here describe both the isolation ofpeptides 
from MHC class II molecules of the macrophage cell line 
P388D1  infected with L.  donovani,  and the use of the de- 
rived peptide sequence to rescue the parasite's peptide do- 
nor protein. Leishmania parasites  were chosen because they 
are strictly intracellular pathogens residing exclusively within 
the late endosomal compartment of macrophages, profes- 
sional APCs of MHC class II-associated peptides. In addi- 
tion, T  cells primarily of the CD4+  phenotype appear to 
play a major role in the host defense against  these parasites 
(34,  36-39). The infection and processing of parasite anti- 
gens by the P388D1  macrophages did not change the level 
of the class II molecules expression but it clearly modified 
the  HPLC  pattern  of the  peptides  extracted from  these 
molecules. Several distinct HPLC peaks were consistently 
present on the peptide preparation obtained from the in- 
fected macrophages and absent in the preparations obtained 
from  noninfected  cells.  These  results  suggest  that  these 
peaks  contain  parasite  peptides  that  were  processed  and 
presented by the infected macrophages. However it is also 
possible  that the  infected macrophages would abnormally 
process selfpeptides that could too be present in the unique 
HPLC peaks.  Indeed, peptide sequences that support this 
possibility  were  obtained  from  these  peaks  (see  below). 
These two  possibilities  are however not  mutually exclu- 
sive. Unfortunately, in several cases the peptide amino acid 
sequence could not be determined because of the limita- 
tions of the protein sequencer system used in these studies 
that has a sensitivity in the order ofnanomoles ofpeptide, a 
concentration that was only rarely obtained for the peptides 
isolated  from  the  infected  macrophages.  This  problem 
should be easily solved in future studies by the use of the 
recent  developed technologies like  the  Laser Desorption 
Mass Spectrometry (LDMS) or the combination of micro- 
capillary RP-HPLC  separation  coupled with  electrospray 
ionization tandem mass  spectrometry (35).  The sensitivity 
of these methodologies is in the order of a few fentomoles 
of peptides.  Despite  the  methodological limitation,  three 
peptides could be sequenced from the infected macrophage 
preparation. One of these peptides had sequence homology 
with elongation factor of several origins including Leishma- 
nia, and another peptide was highly homologous to glycer- 
aldehyde-3-phosphate  dehydrogenase  of various  species. 
These two peptides were not considered of interest because 
of their ubiquitous distribution. The third peptide did not 
appear to be homologous to any known protein and conse- 
quently was  employed to instruct the rescue of a possible 
parasite donor protein. The peptide sequence was initially 
used  to  instruct  the  design  of an  oligonucleotide  sense 
primer which was  used in combination with an oligo dT 
nucleotide (anti-sense primer) to amplify by PCR a DNA 
fragment from L. donovani  cDNA. The DNA fragment am- 
plified ('--~300 bp) was  cloned and subsequently sequenced 
which unequivocally confirmed the sequence of the pep- 
tide based primer including the carboxy-terminal glutamic 
acid  codon that was  not  deliberately incorporated in  the 
primer  sequence.  Using  this  cloned  DNA  fragment  as 
probe the corresponding L.  donovani  gene  (Ld peptide/  a 
gene) was successfully  cloned from a L.  donovani  cDNA li- 
brary.  The cloned Ld peptide/gene has  an  open  reading 
frame of 525 bp and has no homology with any other gene 
sequence so far reported. In addition the gene is apparently 
broadly distributed and expressed among the Leishmania ge- 
nus because its corresponding mlLNA transcript is present 
not only in L.  donovani  but also in other species  of this ge- 
nus in both amastigote and promastigote forms of the para- 
site cell cycle. 
Despite the limited accuracy of the amino acid sequence 
determined for the  MHC  class II-associated peptides  and 
the consequent need to use a degenerate primer for PCR, 
the sequence of the cloned gene matches with the five car- 
boxy-terminal residues  of the  original  peptide  sequence 
(KVFDE). It is important to emphasize that a sequence of 
only seven amino acids was used to design the primer for 
the PCR and that the carboxyl-terminal glutamic acid of 
the peptide sequence was  not used to design  the primer. 
The peptide sequence lies in the positions 126-130 of the 
175 amino acids of the deduced protein sequence. It is in- 
teresting to note that coincidentally this is an area of the 
protein in which a very high antigenic index is deduced us- 
ing the algorithm described by Jameson and Wolf (1988)  to 
predict antigenic epitopes. However circumstantial, this in- 
formation is consistent with the fact that this very epitope 
was processed and presented by L. donovani-infected P388D 1 
macrophages. 
Once the Ld peptide/gene was cloned and sequenced its 
expression  as  a  fusion  protein  was  achieved  using  the 
pGEX 2T expression vector and the purified GST-fusion 
protein was used to investigate the antigenic relation of the 
recombinant  protein  with  L.  donovani.  This  relationship 
was  demonstrated  using  both  antibody  and  T  cell  re- 
sponses.  First,  mice and rabbits immunized with the fusion 
protein  developed  antibodies  that  recognized  a  23-kD 
molecule (Ldp 23)  on the cell surface of L.  donovani  pro- 
mastigotes.  The small  molecular mass  difference between 
the recombinant leishmanial protein and the Ldp 23 might 
be due to post translational modifications such as glycosyla- 
tion  of the  native  protein  (one  glycosylation site  at  the 
amino acid positions 68-70 is present in this molecule as is 
indicated by its deduced protein sequence). The surface ex- 
pression of  Ldp 23 is of much interest because several leish- 
mania surface proteins are buried beneath the  glycoinosi- 
tolphospholipids and lipophosphoglycans (LPG) glycocalyx 
coat present in  these  parasites  (40).  However, recent re- 
ports (40-42) described a novel hydrophilic protein called 
gene B protein, that is exposed on the cell surface of L. ma- 
jor promastigotes. This protein targets to the parasite's sur- 
face apparently by binding to LPG via an unusual  amino 
acid repeat that is related to the peptidoglycan binding do- 
main  of protein A  from Staphylococcus  aureus.  Similarly to 
the gene B  protein, the deduced protein structure of Ldp 
23 indicates a high hydrophilicity and high content in Lys 
residues. However, whether or not Ldp 23 also  targets to 
the parasite's surface via binding to LPG remains to be in- 
vestigated. 
1430  Cloning a Leishmania Gene Using an MHC Class II-associated  Peptide At  the  T  cell level,  the  relationship  of Ldp  23  with 
L.  donovani was initially carried  out  using specific T  cells 
purified from the lymph node  of mice immunized with 
L. donovani. These cells were specifically stimulated to pro- 
liferate by Ldp 23-pulsed APC,  thus  confirming its  leish- 
manial  origin.  Moreover,  strong  evidence  indicates  that 
Ldp 23 is preferentially involved in the activation of the Th 
1 pattern of cytokine response which pattern is correlated 
with  resistance  to  infection with  Leishmania parasites  (34, 
44-46).  This observation is particularly interesting in  that 
Ldp 23 is selectively activating Th  1 clones even from the 
highly  susceptible BALB/c  mice which,  as  is  well  docu- 
mented,  have  a  strong  genetic  bias  towards  the  develop- 
ment of the susceptible Th 2 type of response (43).  A simi- 
lar selective induction ofTh 1 cytokines in human peripheral 
blood  mononuclear  cells,  has  been  recently  reported  for 
another Leishmania recombinant antigen (44). 
The  cloning of Ld peptide/gene  and  expression of the 
corresponding  protein  constitute  interesting  findings  for 
the studies concerning vaccine development to leishmania- 
sis. This  possibility is  supported by the  facts  that  the  Ld 
peptide/gene  is broadly distributed  among the  Leishmania 
genus; it is expressed in both amastigote and promastigote 
forms  (logarithmic  and  stationary  phases)  of  all  species 
tested;  that  the  corresponding Ldp  23  is localized on the 
cell surface of the parasite is particularly attractive for vac- 
cine development because this molecule can be a good tar- 
get  for  immunological  intervention  on  the  parasite/host 
cell  interaction.  In addition Ldp 23 appears to induce pref- 
erentially Th 1 clones. The expansion of these studies and 
the analysis the Ldp 23 immunogenic epitopes for both hu- 
mans and mice are in progress. 
The results presented here support the  idea  that MHC 
class II molecules-associated peptides can be used to rescue 
a pathogen protein that is recognized and processed by the 
APCs.  The  virtue  of this  strategy is  that  it  goes  directly 
from  the  recognized  peptide  to  the  pathogen  gene  and 
from there to the peptide donor protein. Therefore the se- 
lection of a pathogen protein that might be involved in the 
host/pathogen interaction is achieved without the need of 
T  cell clones and a battery of many different synthetic pep- 
tides.  One  limitation  of  this  approach  is  however  the 
chance that the rescued protein may not be relevant to the 
host/pathogen  interaction,  because  there  is  no  previous 
knowledge of its participation in the infectious process and 
also because of pathogen's vast antigenic universe that can 
be processed and presented by the APCs. Nevertheless, the 
use of good experimental animal models can be helpful in 
this context. For instance, in the leishmania system, a large 
number of mouse strains are relatively resistant to the infec- 
tion with L. donovani. In contrast, L. amazonensis and L. major 
cause  severe  diseases  in  many  strains  of mice  (37,  45). 
Therefore the  infection  of macrophages with  L.  donovani 
may be an interesting source of peptides to rescue cross re- 
active proteins that could be potentially useful for vaccine 
development not only against this parasite but also to other 
members of the Leishmania genus. Indeed, good protection 
of  BALB/c mice against L. major  infection has been achieved 
with a 72-kD protein from L. donovani (46). 
Finally these results clearly point to a feasible alternative 
strategy for the purification of useful reagents for the devel- 
opment  of both  vaccines  and  immunological  diagnostic 
tools  not  only  against  Leishmania  infection  but  also  for 
other diseases caused by intracellular pathogens. 
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